EMPEROR will be the first global Phase 3 study to assess the effects of a potential disease-modifying therapy on seizures and multiple aspects of cognition and behavior in patients with Dravet syndrome.
Montgomery multiplication kernel from the OpenSSL big number library, compiled by gcc -O3 (left) and STOKE (right). The STOKE code is 16 lines shorter, 1.6x faster, and slightly faster than expert …
This Investment Guide (this “presentation”) and the information contained in it relates to a hypothetical investment in Stoke Space (“Stoke”). This presentation contains insights derived from public, yet not …
On February 13, 2026, the Board of Directors (the “Board”) of Stoke Therapeutics, Inc. (the “Company”) approved a discretionary bonus of $697,125 for Ian F. Smith, the Company’s Chief Executive Officer …
Speaker disclosures Received honoraria for presenting at educational events and advisory boards Consultancy work for Biocodex, GW / Jazz Pharma, Encoded Therapeutics, Servier, Stoke …
We thank the investigators, healthcare providers, research staff, patients, and caregivers who participated in the MONARCH and ADMIRAL studies. These studies were funded by Stoke …
On January 21, 2026, Stoke Therapeutics, Inc. (the “Company”) entered into a new lease for its corporate headquarters and laboratory with NWALP PHOP Property Owner LLC, located at 245 Fifth …